Astex urged to hold out for more from Otuska; AstraZeneca sells landmark building; Sanofi close to Elder deal;

@FiercePharma: Glaxo said to be near $1.6B Lucozade-Ribena sale to Japan's Suntory. Latest in series of brand sales. ICYMI yesterday | Follow @FiercePharma

@EricPFierce: Bristol-Myers Squibb flees high cost of East Coast with new center in Tampa, FL. Moving some jobs from NJ. Report | Follow @EricPFierce

@CarlyHFierce: Departure of new Vivus CEO Zook tops the list of this week's hirings, firings & other movements in pharma/biotech. Chutes & Ladders | Follow @CarlyHFierce

> Analysts suggest Astex Pharmaceuticals ($ASTX) should hold out for a much better deal than the $886 million Abilify-maker Otuska offered this week. Story

> Amgen ($AMGN) has sent a letter to healthcare providers warning that its drugs Neupogen and Neulasta have been associated with potentially fatal capillary leak syndrome (CLS). Report

> Biotech investor David Blech says if he had left well enough alone, he would be a billionaire, not a prisoner. Story

> AstraZeneca ($AZN) has sold the landmark Rollins Building in Fairfax, DE, to investors for a reported $10.5 million. Report

> Novartis ($NVS) said today that it has an exclusive global licensing and research collaboration agreement with Louisville, KY-based Regenerex to use its Facilitating Cell Therapy (FCRx) platform in kidney transplantation. Release | More from FierceBiotech

Medical Device News

@FierceMedDev: Enzymatics jumps into next-gen Dx space with $50M startup buy. More | Follow @FierceMedDev

@MarkHFierce: Better sanitation is linked to more Alzheimer's cases. Article | Follow @MarkHFierce

@MichaelGFierce: Myriad rolls out next-gen Dx for 8 major cancers. Story | Follow @MichaelGFierce

> Rented Medtronic tools linked to possible disease exposure. News

> Enzymatics jumps into next-gen Dx space with $50M startup buy. Report

> Report: KKR favored bidder in Panasonic's billion-dollar health unit sale. Story

> India advances effort to modernize medical device regs. Item

Biotech News

@FierceBiotech: In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Article from FierceBiotech IT | Follow @FierceBiotech

@JohnCFierce: Crowdfunding cash for biotech startup Perle (diabetes). Press release | Follow @JohnCFierce

@Ry_McBride: UPDATED: No end of biotech IPO frenzy in sight. Special report | Follow @Ry_McBride

@EmilyMFierce: Making iPS cells safer for use in humans through the study of a cellular odd fellow. More from Stanford | Follow @EmilyMFierce

> Novartis strikes stem cell deal to aid transplant patients. Story

> NYT: Blech says he could have been a biotech billionaire. Article

> Under FDA priority review, Mallinckrodt's pain med succeeds in PhIII. More

And Finally... Reports say that Sanofi ($SNY) is closing in on a deal to buy India's Elder Pharma. Story

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.